Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
Qlaris Bio appointed Fred Guerard, PharmD, as its president and CEO, according to a press release.
The company is entering phase 3 development of QLS-111, a novel eye drop for lowering IOP in patients with open-angle glaucoma and ocular hypertension (OHT). In a statement to Healio, Guerard said he is coming to the company at an important time, with “promising results” coming out of the phase 2 Osprey and Apteryx clinical trials.
“As QLS-111 advances into phase 3 clinical development, Qlaris Bio is at a pivotal moment — building on encouraging clinical data and a